Uterine and cervical cancers remain major global health challenges, particularly in low- and middle-income countries where the incidence and mortality rates are disproportionately high. Despite advances in surgery, chemotherapy, and radiotherapy, treatment outcomes for advanced and recurrent disease remain unsatisfactory. Recent developments in immunotherapy, including immune checkpoint inhibitors, therapeutic vaccines, and adoptive cell transfer, have introduced promising new strategies in gynecologic oncology. Clinical trials demonstrate improved overall survival and durable responses in patients with PD-L1–positive and microsatellite instability-high (MSI-H) tumors. However, variability in response rates, immune-related toxicities, and economic barriers pose significant challenges to widespread clinical adoption. This article explores the current role, effectiveness, and limitations of immunotherapy in uterine and cervical cancers, highlights recent breakthroughs, and discusses future perspectives for integrating immunotherapy into multimodal treatment approaches

Uterine cancer; Cervical cancer; Immunotherapy; Immune checkpoint inhibitors; HPV vaccine; Adoptive T-cell therapy; PD-L1 expression; Microsatellite instability; Gynecologic oncology; Personalized medicine.

Bhatla, N., Aoki, D., Sharma, D. N., & Sankaranarayanan, R. (2018). Cancer of the cervix uteri. International Journal of Gynecology & Obstetrics, 143(Suppl 2), 22–36.

Cohen, P. A., Jhingran, A., Oaknin, A., & Denny, L. (2019). Cervical cancer. The Lancet, 393(10167), 169–182.

Бабажанова, Ш. Д., Любчич, А. С., & Джаббарова, Ю. К. (2021). Факторы, способствовавшие неблагоприятному исходу при преэклампсии. Фундаментальная и клиническая медицина, 6(1), 27-31.

Bacci, A., Hodorogea, S., Khachatryan, H., Babojonova, S., Irsa, S., Jansone, M., ... & Lazzerini, M. (2018). What is the quality of the maternal near-miss case reviews in WHO European Region? Cross-sectional study in Armenia, Georgia, Latvia, Republic of Moldova and Uzbekistan. BMJ open, 8(4), e017696.

Babazhanova, S. D., Lyubchich, A. S., & Lyubchich, N. I. (2022). Efficacy of using controlled uterine balloon tamponade for stopping atonic postpartum hemorrhage. Journal of obstetrics and women's diseases, 71(1), 5-10.

Chung, H. C., Ros, W., Delord, J. P., Perets, R., Italiano, A., Shapira-Frommer, R., ... & Leary, A. (2019). Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology, 37(17), 1470–1478.

Бабажанова, Ш. Д. (2009). Исходы при фетоплацентарной недостаточности различной степени тяжести в зависимости от акушерской тактики. Врач-аспирант, 37(10), 910-914.

Colombo, N., Dubot, C., Lorusso, D., Caceres, M. V., Hasegawa, K., Shapira-Frommer, R., ... & Leary, A. (2021). Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. New England Journal of Medicine, 385(20), 1856–1867.